Since anti-GPC1 mAb specifically target GPC1 positive tumor cells, we consider that anti-GPC1 mAb would be quite effective therapy for treatment of ESCC cells which remain after cisplatin therapy. This evidence concerns the gene GPC1 and esophageal squamous cell carcinoma.